linjc16/ctgov huggingface dataset:
Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma

Study Overview
=================
Brief Summary
-----------------
To Calculate the amount radiation the lung receives in patients receiving Yttrium-90 for Liver Cancer.

Detailed Description
-----------------
To calculate the delivered lung dose using quantitative volumetric analysis in a cohort of patients with unresectable hepatocellular carcinoma who undergo selective internal radiation therapy (SIRT) with Yttrium-90 glass microspheres (TheraSphere®)-and compare this analysis to the lung dose estimated by established criteria. In addition, this study, will summarize the pre and post-treatment clinical data to describe the URMC Y-90 experience.

Official Title
-----------------
Analysis of Lung Dose Using Volumetric Analysis in Patients Treated With Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma

Conditions
-----------------
Liver Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults ≥ 18 years with no upper limit.-Receiving Y-90 Therasphere liver directed therapy Pathology proven diagnosis of hepatocellular carcinoma, metastatic colon cancer or other metastatic diseases to be treated with SIRT (Y-90) surgical resection not feasible at time of initiation of pre-treatment workup -> 6 months projected life span ECOG 0-2 Exclusion Criteria: previous radioembolization of one or more liver lobes or segments without available treatment planning and procedural documentation ie. at another facility prior to URMC Y-90 radioembolization.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung dose measured with actual lung mass vs Lung dose measured with conventional method. | Lung dose measured with actual lung mass vs Lung dose measured with conventional method which assumes 1 kg for all patients. Patient will be receiving this treatment even if not enrolled on this study. The study is NOT about the intervention given to the patient. The study is to determine the best way to measure the radiation dose normal tissue (the lung specifically) receives during this standard treatment. | 1 month after treatment. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Liver Neoplasma, Lung Radiation dose
Evaluation of Malondialdehyde in Periodontal and Cardiovascular Disease

Study Overview
=================
Brief Summary
-----------------
Malondialdehyde (MDA) plays a key role in endothelial function and may be a link for the known interaction of periodontitis and coronary heart disease (CHD). The investigators compared the impact of gingival health, periodontitis (CP), CHD or of both diseases (CP+CHD) on saliva and serum MDA levels.

Detailed Description
-----------------
The aim of this study was to evaluate a possible association between both saliva and serum MDA levels in patients with CP and with CHD and if the serum MDA levels are mediated by serum CRP

Official Title
-----------------
Analysis of Serum and Salivary Malondialdehyde and Lipid Profile Levels in Patients With Periodontal and Cardiovascular Diseases

Conditions
-----------------
Metabolic Disease

Intervention / Treatment
-----------------
* Other: Observation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presence of at least twenty teeth CP with a minimum of 40% of sites with a clinical attachment level (CAL) ≥2mm and probing depth (PD) ≥4mm; Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs Presence of ≥40% sites with bleeding on probing (BOP) Exclusion Criteria: Intake of contraceptives Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study Status of pregnancy or lactation Previous history of excessive drinking Allergy to local anaesthetic Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control<br>Healthy patients | Other: Observation<br>* Evaluation of Malondialdehyde level and correlation of Malondialdehyde level with periodontal and cardiovascular disease<br>|
| Periodontitis<br>Patients with periodontal disease | Other: Observation<br>* Evaluation of Malondialdehyde level and correlation of Malondialdehyde level with periodontal and cardiovascular disease<br>|
| Cardiovascular<br>Patients with cardiovascular disease | Other: Observation<br>* Evaluation of Malondialdehyde level and correlation of Malondialdehyde level with periodontal and cardiovascular disease<br>|
| Periodontitis+Cardiovascular<br>Patients with both periodontal and cardiovascular disease | Other: Observation<br>* Evaluation of Malondialdehyde level and correlation of Malondialdehyde level with periodontal and cardiovascular disease<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Malondialdehyde levels |  | 1 year |
Mesenteric Panniculitis : Review of Consecutive Abdominal MDCT Examinations With a Matched-pair Analysis

Study Overview
=================
Brief Summary
-----------------
Mesenteric panniculitis is a benign inflammatory condition that involves the adipose tissue of the intestinal mesentery. Clinical manifestations are uncommon, non specific and atypical. Mesenteric panniculitis is thus most often an incidental finding during an investigation for other reason, mostly on computed tomography scans. The rate of malignancy in patients with mesenteric panniculitis, especially urogenital and gastrointestinal adenocarcinomas or lymphomas, has been reported to be as high, thus suggesting that there may be a relationship between mesenteric panniculitis and progression of an underlying malignancy or the risk of a future malignancy.

Detailed Description
-----------------
The aim was: to estimate the prevalence of mesenteric panniculitis. to study relationship between mesenteric panniculitis and malignancy. to investigate the 5-year outcome of patients with mesenteric panniculitis for the development of malignancy.

Official Title
-----------------
Mesenteric Panniculitis : Review of Consecutive Abdominal MDCT Examinations With a Matched-pair Analysis

Conditions
-----------------
Mesenteric Panniculitis

Intervention / Treatment
-----------------
* Other: Review of multidetector row computed tomography scans


Participation Criteria
=================
Eligibility Criteria
-----------------
inclusion criteria: Patients with a CT scan from January to August 2008 Patients with diagnosis of mesenteric panniculitis on CT scan exclusion criteria: Patients with disease that may cause mesenteric infiltration

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cases<br>patients with a CT scan from January to August 2008 for which mesenteric panniculitis was diagnosed | Other: Review of multidetector row computed tomography scans<br>* multidetector row computed tomography scans<br>|
| controls<br>patients with a CT scan from January to August 2008 for which mesenteric panniculitis wasn't diagnosed and matched by gender and age with cases patients | Other: Review of multidetector row computed tomography scans<br>* multidetector row computed tomography scans<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mesenteric panniculitis | mesenteric panniculitis is identified on the basis on the presence of three of the following 5 signs on CT scan: higher attenuation of the fat of the root of the small bowel mesentery, a pseudo mass smoothly displacing neighboring structures with a hyperdense pseudocapsule surrounding the mesenteric fat, lymph nodes within the fatty pseudo mass and a hypodense halo around the nodes and the blood vessels | Day 0 |
Evaluation of SCOUT DS in Subjects With Type 2 Diabetes #2

Study Overview
=================
Brief Summary
-----------------
The primary objective of the trial is to collect SCOUT DS and Hemoglobin A1c measurements of subjects who have been diagnosed with Type 2 diabetes.

Detailed Description
-----------------
Previous studies have excluded subjects with Type 2 diabetes. The primary objective of this study is to correct an imbalance in the disease prevalence of the data set used to develop the SCOUT DS diabetes screening algorithm.

Official Title
-----------------
An Evaluation of a Noninvasive Diabetes Screening Device in Subjects at the TCOYD Diabetes Conference

Conditions
-----------------
Diabetes Mellitus, Non-Insulin Dependent

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age greater than or equal to 18 years Self-reported diagnosis of type 2 diabetes No Self-reported diagnosis of type 2 diabetes Exclusion Criteria: Less than 18 years of age Diagnosed with type 1 diabetes Known to be pregnant (Self Reported) Receiving dialysis or having known renal compromise Scars, tattoos, rashes or other disruption/discoloration on the left volar forearm. Known to have, or at risk for, photosensitivity reactions ( e.g., sensitive to ultraviolet light, or taking medication known to cause photosensitivity)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Those with Type 2 diabetes<br>270 subjects with Type 2 diabetes | |
| Non diabetic<br>30 healthy subjects | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Continuing validation of SCOUT DS algorithm | Collect SCOUT DS and Hemoglobin A1c measurements of subjects with Type 2 Diabetes | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Type 2 Diabetes, Adults 18 years and older, Taking Control of Your Diabetes Health Fair
Modified Second Layer Repair for Distal Penile Hypospadias

Study Overview
=================
Brief Summary
-----------------
to evaluate a modification to snodgrass technique in second layer closure of distal penile hypospadias

Detailed Description
-----------------
In our study, we applied a new modification by using an intervening layer of a de-epithelialized ventral derma-dartos flap for neourethral covering. we present our newly applied technique and its impact on the success rate.

Official Title
-----------------
Modified Tubularized Incised Plate Urethroplasty (Snodgrass) For Distal Hypospadias Repair in a Circumcised Patient With the Use of a Derma -Dartos Flap for Second Layer Closure: Our Initial Experience

Conditions
-----------------
Hypospadias

Intervention / Treatment
-----------------
* Procedure: Derma -Dartos Flap for second layer closure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All male patient with distal penile hypospadias aged less than 18 Exclusion Criteria: Patients with penile rotation or hypoplastic urethral plate were excluded from the study

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: intervention group<br>patients underwent our newly modified technique for hypospadias repair | Procedure: Derma -Dartos Flap for second layer closure<br>* usage of Derma -Dartos Flap for second layer closure of a distal penile hypospadias in circumcised patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| urethro-cutaneous fistula | presence of urethro-cutaneous fistula after closure of hypospadias as assess by inspection for the presence of urinary fistula | 1 year follow up |
Correlation Between the Change of Peripheral Lymphocyte Subsets and Clinically Amyopathic Dermatomyositis Combined With Rapidly Progressive Interstitial Lung Disease

Study Overview
=================
Brief Summary
-----------------
Acute respiratory distress syndrome (ARDS) occurs in Clinically Amyopathic Dermatomyisitis(CADM) combined with Rapidly Progressive Interstitial Lung Disease(RPILD) within 1-3 months, which leads to death of patients and is difficult to treat. Even if high doses of glucocorticoids are ineffective, there is no recommended treatment for such patients, which is a huge medical challenge.Lymphopenia is an independent risk factor for death in CADM-RPILD, but the cause of lymphopenia is unclear.In this study, the level of lymphocyte subsets in peripheral blood was detected by flow cytometer, in order to further clarify the pathogenesis of the disease, to facilitate clinical guidance of treatment, and to improve the survival rate of patients.In addition, studies have shown that INF-α levels are significantly increased in CADM patients combined with RPILD and are a poor prognostic factor for CADM-RPILD, suggesting that the interferon system plays a role in the pathogenesis of CADM and can be used as an evaluation index of the severity of CADM-RPILD.In this study, the levels of relevant cytokines including INF and IL-2, IL-17, IL-18, IL-6 were detected simultaneously, and the relationship between disease activity and lymphocyte subsets was analyzed, and the changes of lymphocyte subsets after Tofacitinib treatment were determined in order to facilitate clinical guidance of treatment.

Official Title
-----------------
Correlation Between the Change of Peripheral Lymphocyte Subsets and Clinically Amyopathic Dermatomyositis Combined With Rapidly Progressive Interstitial Lung Disease

Conditions
-----------------
Clinically Amyopathic Dermatomyisitis(CAMD)

Intervention / Treatment
-----------------
* Drug: Tofacitinib 5 MG [Xeljanz]


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age≥18 years old,≤80years old,no gender limit; CADM of diagnosis according to Sontheimer diagnostic criteria; combined with Rapidly Progressive Interstitial Lung Disease Exclusion Criteria: Age<18years old，>80years old; potential malignant tumor

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Tofacitinib 5 MG [Xeljanz]|Treatment with Tofacitinib|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The level of a lymphocyte in a lymphocyte subset correlates with disease activity. |  | 3 month |
Valvular Heart Disease Registry

Study Overview
=================
Brief Summary
-----------------
Patients undergoing transcatheter valvular interventions will be prospectively included into the present registry. Baseline, procedural and follow-up data will be collected and analyzed to adress various issues in the field of percutaneous valvular interventions.

Official Title
-----------------
Valvular Heart Disease Registry - Observational Study of Percutaneous Valvular Interventions

Conditions
-----------------
Valvular Heart Disease

Intervention / Treatment
-----------------
* Device: Transcatheter valvular repair or replacement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Severe valvular defect planned for valvular intervention Exclusion Criteria: - No informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients undergonig transcatheter valvular interventions<br> | Device: Transcatheter valvular repair or replacement<br>* Transcatheter valvular repair (predominantly MitraClip for mitral regurgitation) or replacement (predominantly transcatheter aortic valve implantation for aortic stenosis)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality |  | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular mortality |  | 10 years | 
| NYHA status |  | 10 years | 
| Grade of mitral regurgitation |  | 10 years |
Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours

Study Overview
=================
Brief Summary
-----------------
At present, diagnosis of oligodendroglioma is made on histological and radiographic criteria in the French Mayo-Ste Anne classification. The less frequent grade A oligodendrogliomas are characterized by no vascular contrast on RMN evaluation comparatively to grade B forms. This benign histological subtype relapses in few cases with a more aggressive histology. To determine these relapsed cases at diagnosis, a collection of tumour begun in February 2004. Then, our study was designed to identify diagnostic molecular and metabolic markers that could eventually be used as a signature characterising grade A versus grade B oligodendrogliomas. The molecular analysis will use genomic techniques like allelotyping study, quantitative real-time PCR, gene sequencing , serial analysis of genomic expression and immunohistochemistry, since the metabolic study will be the spectroscopic examination of in vivo tumour. This study will include paediatric and adult patients followed for oligodendrogliomas, medulloblastomas and gliomas to compare the different tumour signatures. All these results will be correlated to survival and clinical features.

Official Title
-----------------
Research of Molecular and Metabolic Diagnostic Markers in Oligodendrogliomas A and B Comparatively.

Conditions
-----------------
Oligodendrogliomas

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Paediatric and adult patients (> 1 year of age) Patient with oligodendroglioma or medulloblastoma or glioma Possibility of 3 year follow-up Patient consent obtained Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Brain tumours, oligodendrogliomas, allelotyping, SAGE, Presence of molecular abnormalities statistically linked to survival or response to chemotherapy
Yervoy Pregnancy Surveillance Study

Study Overview
=================
Brief Summary
-----------------
The study is a global safety surveillance study of pregnancy outcomes in women who were exposed to ipilimumab during pregnancy and pediatric outcomes up to 5 years of age

Official Title
-----------------
A Global Enhanced Pharmacovigilance Pregnancy Surveillance Study of Pregnant Women Exposed to Yervoy With 5 -Year Pediatric Follow-up

Conditions
-----------------
Melanoma

Intervention / Treatment
-----------------
* Drug: Yervoy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Documented exposure to Yervoy while pregnant or within 90 days of discontinuing treatment Exclusion Criteria: Women whose ipilimumab exposure is outside the window of pregnancy exposure Pregnancies for which there is only paternal exposure to Yervoy Other protocol defined inclusion/exclusion criteria could apply
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Women Exposed to Yervoy (ipilimumab) During Pregnancy<br>Women Exposed to Yervoy (ipilimumab) During Pregnancy and the Children from These Pregnancies | Drug: Yervoy<br> <br> * Other names: ipilimumab;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of structural birth defects in infants born to mothers exposed to Yervoy while pregnant |  | Birth up to 12 months | 
| Incidence of chromosomal birth defects in infants born to mothers exposed to Yervoy while pregnant |  | Birth up to 12 months | 
| Delays in developmental milestones |  | Birth up to 5 Years | 
| Clinical Signs of Immune or Endocrine Dysfunction |  | Birth up to 5 Years | 
| Clinical Signs of Autoimmune Disorders |  | Birth up to 5 Years | 
| Clinical Signs of Serious Infections and Malignancy |  | Birth up to 5 Years | 
| Adverse Pregnancy Outcomes | Elective or spontaneous abortion, fetal death/stillbirth, pre-term delivery, ectopic or molar pregnancy | Time of Conception up to Birth |